Navigation Links
Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
Date:8/17/2011

MIAMI, Aug. 17, 2011 /PRNewswire/ -- Nuovo Biologics, LLC has announced a collaboration with Dr. Lester Mandelker a Largo, Florida veterinarian. Dr. Mandelker will supervise all small non consumable animal veterinary related activities implemented by the Company in its pursuit of FDA/CVM NADA approvals for Panavira™ including (but not limited to) respiratory disease caused by viral infections, canine malignant melanoma, feline leukemia (FeLv) and feline immune deficiency (FIU).

Dr. Mandelker will assist the company in developing a veterinary research organization designed to train veterinarians to perform and manage clinical research.  Dr. Mandelker will help recruit both his own patients and other qualified veterinarians to bring their patients to participate in the pilot and field studies for Panavira™ and other veterinary products.

Dr. Mandelker who maintains active memberships in AVMA, FVMA, AAHA, FVMA, ABVP and the FAAVPT has been in private practice since 1972 at the Community Veterinary Hospital, in Largo Florida, which is an AAHA Certified Hospital.

Over the last several decades Dr. Mandelker has maintained a high degree of peer respect and acknowledgement. A Past President of the Pinellas County (Florida) Veterinary Medical Association, he was selected among the nation's top veterinarians in 2006 & 2007 by the Consumer's Research Council of America and was Chairman of Examination Committee of the American Board of Veterinary Practitioners from 1900 to 1992.

Dr. Mandelker is a Diplomat of The American Board of Veterinary Practitioners and is certified in Canine and Feline Medicine.  His Specialty Interest is Pharmacology, Nutraceuticals and Antioxidants. Dr. Mandelker is also a Fellow of the American Academy of Pharmacology and Therapeutics (FAAVPT).

Dr. Mandelker has published over 175 scientific articles on pharmacology, medicine and nutraceuticals in journals such as: AVMA journal, VM/SAC, Veterinary Forum and The Veterinary Clinics of North America.  He has done extensive work in pharmacology and first introduced various human pharmacological agents to veterinary medicine and is in demand as a speaker on Veterinary Pharmacology.

Nuovo Biologics is a Florida based animal health company dedicated to the development of innovative, safe and efficacious drugs, biologicals and supplements that enhance animal health and wellness.


'/>"/>
SOURCE Nuovo Biologics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Expanded Lipoprotein Testing, VAP® Cholesterol Test Discussed at National Lipid Association Summer Clinical Lipid Update
3. Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting
4. Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
5. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
6. New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
7. VAP(R) Cholesterol Test Now Available at ANY LAB TEST NOW(R)
8. Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia
9. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
10. Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
11. VAP Cholesterol Test Helps In Search For New Heart Disease Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):